Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...
Medical Marketing & Media2d
Novo, Lilly and Novartis lead pharma’s stellar ad performance at Oscars
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
BioSpace2d
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
Fierce Pharma2d
Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...